An indolylquinoline derivative promotes apoptosis in human lung cancer cells by impairing mitochondrial functions

Apoptosis

Volumn 20, Issue 11, 2015, Pages 1471-1482

  Liu, Chun Yen ^a   Wu, Pei Tsen ^a   Wang, Jing Ping ^a   Fan, Po Wei ^a   Hsieh, Chang Hung ^a   Su, Chun Li ^a   Chiu, Chien Chih ^b   Yao, Ching Fa ^a   Fang, Kang ^a  

^a NATIONAL TAIWAN NORMAL UNIVERSITY   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Apoptosis; Human non small cell lung cancer cells; Indolylquinoline; p53; RNA interference

Indexed keywords

3[(7 ETHYL 1H INDOL 3 YL) METHYL] 2 METHYLQUINOLINE; ANTINEOPLASTIC AGENT; CYTOCHROME C; MITOCHONDRIAL PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROCASPASE 3; PROTEIN P53; QUINOLINE DERIVATIVE; UNCLASSIFIED DRUG; CASPASE 3; INDOLE; INDOLE DERIVATIVE; QUINOLINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; APOPTOSIS ASSAY; ARTICLE; CANCER INHIBITION; CELL DEATH; CELL VIABILITY; COMET ASSAY; CONTROLLED STUDY; DNA DAMAGE; DOWN REGULATION; DRUG CYTOTOXICITY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IC50; LUNG CANCER CELL LINE; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRION; MOLECULAR WEIGHT; MOUSE; MTT ASSAY; NON SMALL CELL LUNG CANCER; NONHUMAN; PHASE CONTRAST MICROSCOPY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; TUMOR VOLUME; WESTERN BLOTTING; CHEMISTRY; DRUG EFFECTS; GENETICS; LUNG NEOPLASMS; METABOLISM; PATHOPHYSIOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASE 3; CELL LINE, TUMOR; CYTOCHROMES C; DNA DAMAGE; HUMANS; INDOLES; LUNG NEOPLASMS; MITOCHONDRIA; QUINOLINES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84942549290     PISSN: 13608185     EISSN: 1573675X     Source Type: Journal    
DOI: 10.1007/s10495-015-1165-6     Document Type: Article

References (36)

1. Mariette C, Piessen G, Triboulet JP (2007) Therapeutic strategies in oesophageal carcinoma: role of surgery and other modalities. Lancet Oncol 8:545-553
2. Chang A (2011) Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC. Lung Cancer 71:3-10
3. Hida T, Ariyoshi Y, Kuwabara M, Sugiura T, Takahashi T, Takahashi T, Hosoda K et al (1993) Glutathione S-transferase pi levels in a panel of lung cancer cell lines and its relation to chemo-radiosensitivity. Jpn J Clin Oncol 23:14-19
4. Tiseo M, Boni L, Ardizzoni A (2005) Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: does cisplatin versus carboplatin make a difference? J Clin Oncol 23:6276-6277
5. Giovanella BC, Stehlin JS, Wall ME, Wani MC, Nicholas AW, Liu LF, Silber R et al (1989) DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science 246:1046-1048
6. Kanzawa F, Sugimoto Y, Minato K, Kasahara K, Bungo M, Nakagawa K, Fujiwara Y et al (1990) Establishment of a camptothecin analogue (CPT-11)-resistant cell line of human non-small cell lung cancer: characterization and mechanism of resistance. Cancer Res 50:5919-5924
7. Saleem A, Edwards TK, Rasheed Z, Rubin EH (2000) Mechanisms of resistance to camptothecins. Ann NY Acad Sci 922:46-55
8. Afzal O, Kumar S, Haider MR, Ali MR, Kumar R, Jaggi M, Bawa S (2015) A review on anticancer potential of bioactive heterocycle quinoline. Eur J Med Chem 97:871-910
9. Ding Y, Nguyen TA (2013) PQ1, a quinoline derivative, induces apoptosis in T47D breast cancer cells through activation of caspase-8 and caspase-9. Apoptosis 18:1071-1082
10. Sedic M, Poznic M, Gehrig P, Scott M, Schlapbach R, Hranjec M, Karminski-Zamola G et al (2008) Differential antiproliferative mechanisms of novel derivative of benzimidazo[1,2-alpha]quinoline in colon cancer cells depending on their p53 status. Mol Cancer Ther 7:2121-2132
11. Souli E, Machluf M, Morgenstern A, Sabo E, Yannai S (2008) Indole-3-carbinol (I3C) exhibits inhibitory and preventive effects on prostate tumors in mice. Food Chem Toxicol 46:863-870
12. Nakamura Y, Yogosawa S, Izutani Y, Watanabe H, Otsuji E, Sakai T (2009) A combination of indol-3-carbinol and genistein synergistically induces apoptosis in human colon cancer HT-29 cells by inhibiting Akt phosphorylation and progression of autophagy. Mol Cancer 8:100
13. Chakrabarti G, Basu A, Manna PP, Mahato SB, Mandal NB, Bandyopadhyay S (1999) Indolylquinoline derivatives are cytotoxic to Leishmania donovani promastigotes and amastigotes in vitro and are effective in treating murine visceral leishmaniasis. J Antimicrob Chemother 43:359-366
14. Pal C, Raha M, Basu A, Roy KC, Gupta A, Ghosh M, Sahu NP et al (2002) Combination therapy with indolylquinoline derivative and sodium antimony gluconate cures established visceral leishmaniasis in hamsters. Antimicrob Agents Chemother 46:259-261
15. Ramesh C, Kavala V, Raju BR, Kuo C-W, Yao C-F (2009) Novel synthesis of indolylquinoline derivatives via the C-alkylation of Baylis-Hillman adducts. Tetrahedron Lett 50:4037-4041
16. Wang JP, Lin KH, Liu CY, Yu YC, Wu PT, Chiu CC, Su CL et al (2013) Teroxirone inhibited growth of human non-small cell lung cancer cells by activating p53. Toxicol Appl Pharmacol 273:110-120
17. 2/M arrest and apoptosis in oral squamous cell carcinoma by modulating Akt-NF-κB, MAPK, and p53 signaling. Chem Biol Interact 195:224-230
18. Agarwal C, Singh RP, Agarwal R (2002) Grape seed extract induces apoptotic death of human prostate carcinoma DU145 cells via caspases activation accompanied by dissipation of mitochondrial membrane potential and cytochrome c release. Carcinogenesis 23:1869-1876
19. Chipuk JE, Green DR (2008) How do BCL-2 proteins induce mitochondrial outer membrane permeabilization? Trends Cell Biol 18:157-164
20. Elmore S (2007) Apoptosis: a review of programmed cell death. Toxicol Pathol 35:495-516
21. Lakin ND, Jackson SP (1999) Regulation of p53 in response to DNA damage. Oncogene 18:7644-7655
22. Petty TJ, Emamzadah S, Costantino L, Petkova I, Stavridi ES, Saven JG, Vauthey E et al (2011) An induced fit mechanism regulates p53 DNA binding kinetics to confer sequence specificity. EMBO J 30:2167-2176
23. Burris HA 3rd (2009) Shortcomings of current therapies for non-small-cell lung cancer: unmet medical needs. Oncogene 28(Suppl 1):S4-S13
24. Aqil M, Elseth KM, Vesper BJ, Deliu Z, Aydogan B, Xue J, Radosevich JA (2014) Part I-mechanism of adaptation: high nitric oxide adapted A549 cells show enhanced DNA damage response and activation of antiapoptotic pathways. Tumour Biol 35:2403-2415
25. Roos WP, Kaina B (2006) DNA damage-induced cell death by apoptosis. Trends Mol Med 12:440-450
26. Green DR (2005) Apoptotic pathways: ten minutes to dead. Cell 121:671-674
27. Haupt S, Berger M, Goldberg Z, Haupt Y (2003) Apoptosis: the p53 network. J Cell Sci 116:4077-4085
28. Marchetti P, Castedo M, Susin SA, Zamzami N, Hirsch T, Macho A, Haeffner A et al (1996) Mitochondrial permeability transition is a central coordinating event of apoptosis. J Exp Med 184:1155-1160
29. Toledo F, Wahl GM (2006) Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat Rev Cancer 6:909-923
30. Wang Y, Ji P, Liu J, Broaddus RR, Xue F, Zhang W (2009) Centrosome-associated regulators of the G(2)/M checkpoint as targets for cancer therapy. Mol Cancer 8:8
31. Chang C, Zhu YQ, Mei JJ, Liu SQ, Luo J (2010) Involvement of mitochondrial pathway in NCTD-induced cytotoxicity in human hepG2 cells. J Exp Clin Cancer Res 29:145
32. Bose P, Thakur S, Thalappilly S, Ahn BY, Satpathy S, Feng X, Suzuki K et al (2013) ING1 induces apoptosis through direct effects at the mitochondria. Cell Death Dis 4:e788
33. Ji H, Ding Z, Hawke D, Xing D, Jiang BH, Mills GB, Lu Z (2012) AKT-dependent phosphorylation of Niban regulates nucleophosmin- and MDM2-mediated p53 stability and cell apoptosis. EMBO Rep 13:554-560
34. Qian J, Zou Y, Rahman JS, Lu B, Massion PP (2009) Synergy between phosphatidylinositol 3-kinase/Akt pathway and Bcl-xL in the control of apoptosis in adenocarcinoma cells of the lung. Mol Cancer Ther 8:101-109
35. Malki A, Ashry el S (2014) In vitro and in vivo efficacy of a novel quinuclidinone derivative against breast cancer. Anticancer Res 34:1367-1376
36. Pronier E, Levine RL (2015) IDH1/2 mutations and BCL-2 dependence: an unexpected Chink in AML's armour. Cancer Cell 27:323-325